Fed Chair Janet Yellen testified before the US Senate Committee on Banking, Housing, and Urban Affairs. She presented the Fed’s semiannual Monetary Policy Report (MPR) to the Congress. In her prepared remarks, she stated that while valuation seems “stretched” in some areas of the bond market, equities “remain generally in line with historical norms.” Yet in the MPR, which bears her signature, the following observation … Continue reading Biotech Stocks: Invest in Biotech, But at Your Own Risk

With second quarter earnings season coming to an end, focus in the biotech sector is back on pipeline and regulatory updates. Last week’s highlights included Achillion Pharmaceuticals, Inc.’s (ACHN) impressive interim data on its experimental hepatitis C virus (HCV) treatment, Gilead Sciences’ (GILD – Analyst Report) legal victory and Amgen’s (AMGN – Analyst Report) hit and miss on the clinical front. Achillion, which focuses on … Continue reading Biotech Stocks Highlights: A look at Last Week’s Performance

Biogen Idec’s (BIIB) shares were up slightly (0.62%) on the FDA approval of multiple sclerosis (MS) product, Plegridy (peginterferon beta-1a). The FDA approved Plegridy for the treatment of people with relapsing forms of multiple sclerosis (RMS). Plegridy Pen, a ready-to-use autoinjector, or a prefilled syringe can be used to administer Plegridy subcutaneously. Plegridy’s less frequent dosing schedule (once every two weeks) could help it gain … Continue reading Biotech Stocks in Focus: Biogen consolidates, Stock Rated High

Amgen (AMGN) suffered a major setback when its phase III study, FOCUS (CarFilzOmib for AdvanCed Refractory MUltiple Myeloma European Study) on multiple myeloma treatment, Kyprolis did not meet its primary endpoint. The open-label study evaluated Kyprolis versus an active control regimen of low-dose dexamethasone, or equivalent corticosteroids, plus optional cyclophosphamide in patients suffering from relapsed and advanced refractory multiple myeloma. However, the study did not … Continue reading Biotech Stock Update: Amgen Stock Disappoints

The trading session has ended on a higher note as the Dow Jones Industrial Average finished at 16,569.98, up 0.10% and the NASDAQ Composite closed at 4,401.33, up 0.70%. The S&P 500 finished the day 0.28% higher at 1,936.92. During the trading session seven out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day at 700.04, … Continue reading Biotech News: Top Stocks Review For The Week

Shares of MannKind Corp. have been on a wild ride over the past year. Most of this volatility is the result of emotionally-charged retail investors pushing the stock past realistic valuation levels. This stock serves as another glaring example as to why it’s generally a bad idea to follow the crowd when investing in biotech stocks. MannKind Corp. (NASDAQ MNKD) is the latest cult biotech … Continue reading Active Biotech Stock: A Look at Mannkind Corp